The EpiDirect^® MGMT Methylation qPCR Assay represents a new and innovative approach allowing for direct quantification of MGMT promoter methylation by qPCR without prior DNA conversion.

The EpiDirect^® technology is based on our unique INA^® chemistry and includes an EpiPrimer™ oligonucleotide that specifically binds and primes amplification of methylated target DNA.

The assay is able to quantify MGMT promoter methylation using standard real-time PCR instruments* in just two hours with as little as 0.5 ng of unconverted input DNA.

• Standard qPCR instrument procedure
• No need for prior conversion of DNA
• Results in less than 2 hours
• 1.5-3% LoD methylation
• Minimal hands-on time
• 0.5-50 ng input DNA
• CE IVD

The EpiDirect^® MLH1 Methylation qPCR Assay represents a new and innovative approach allowing for direct quantification of MLH1 promoter methylation by qPCR without prior DNA conversion.

The EpiDirect^® technology is based on our unique INA^® chemistry and includes an EpiPrimer™ oligonucleotide that specifically binds and primes amplification of methylated target DNA.

The assay is able to quantify MLH1 promoter methylation using standard real-time PCR instruments* in just two hours with as little as 0.5 ng of unconverted input DNA.

• Standard qPCR instrument procedure
• No need for prior conversion of DNA
• Results in less than 2 hours
• Minimal hands-on time
• 0.5-50 ng input DNA
• For performance evaluation only (from 1 September 2024)

MicroSight^® MSI is a simple and fast method for evaluating microsatellite instability (MSI) status of human DNA. The analysis is based on PentaBase’s proprietary INA^® technology that enables fast and easy detection of microsatellite instability status by real-time PCR and high-resolution melt (HRM) analysis.

MicroSight^® MSI requires very little hands-on time and enables evaluation of patient microsatellite status of purified human genomic DNA in less than one and a half hours for fast treatment guidance of cancer patients.

MicroSight^® MSI can be used for analysis of both paired and unpaired tumour samples. Evaluation of unpaired tumour samples is done by comparison to an included universal reference. Up to 7 unpaired tumour samples can be analysed in each real-time PCR run.

• Used with BaseTyper 48.4 real-time PCR system
• Paired and unpaired sample analysis
• Semi-automatic objective analysis
• Results in less than 2 hours
• Minimal hands-on time
• CE IVD

The PlentiPlex^™ MYD88 qPCR Assay combines high sensitivity with ease-of-use and is designed to work on standard real-time PCR equipment. The PlentiPlex^™ MYD88 L265P assay is based on PentaBase’s novel and selective INA^® technologies including the use of BaseBlockers™ that suppress false positive PCR signals from wild type templates.

• Open qPCR instrument procedure
• 0.6-0.75% MYD88 L265P LOD
• Results in less than 2 hours
• Based on INA^® technology
• Minimal hands-on time
• CE IVD

PlentiPlex™ KIT Mastocytosis qPCR Assay is based on PentaBase’s INA^® technology including Base­Blockers™ that allows for ultra-sensitive detection of low variant KIT D816V allele frequency mutati­ons with a limit of detection (LOD) of just 0.005% in genomic DNA purified from whole blood.

The obtained results of PlentiPlex™ KIT Mastocytosis qPCR Assay are intended for the identification of the KIT D816V mutation as part of the WHO diagnostic criteria to assist the diagnosis of Mastocytosis.

• Open qPCR instrument procedure
• Results in less than 2 hours
• Based on INA^® technology
• 0.005% KIT D816V LOD
• Minimal hands-on time
• 5-300 ng input DNA
• CE IVD

The PlentiPlex^™ MYD88 qPCR Assay combines high sensitivity with ease-of-use and is designed to work on standard real-time PCR equipment. The PlentiPlex^™ MYD88 L265P assay is based on PentaBase’s novel and selective INA^® technologies including the use of BaseBlockers™ that suppress false positive PCR signals from wild type templates.

• Open qPCR instrument procedure
• 0.6-0.75% MYD88 L265P LOD
• Results in less than 2 hours
• Based on INA^® technology
• Minimal hands-on time
• CE IVD